CN102443064A - 一种基于凝血酶活性的双靶向作用的嵌合多肽及其应用 - Google Patents
一种基于凝血酶活性的双靶向作用的嵌合多肽及其应用 Download PDFInfo
- Publication number
- CN102443064A CN102443064A CN2011103427518A CN201110342751A CN102443064A CN 102443064 A CN102443064 A CN 102443064A CN 2011103427518 A CN2011103427518 A CN 2011103427518A CN 201110342751 A CN201110342751 A CN 201110342751A CN 102443064 A CN102443064 A CN 102443064A
- Authority
- CN
- China
- Prior art keywords
- chimeric polyeptides
- fragment
- hmgb1
- seq
- sequence
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 230000000694 effects Effects 0.000 title abstract description 40
- 108091006116 chimeric peptides Proteins 0.000 title abstract description 17
- 108090000190 Thrombin Proteins 0.000 title abstract description 12
- 229960004072 thrombin Drugs 0.000 title abstract description 12
- 230000008685 targeting Effects 0.000 title abstract 4
- 239000012634 fragment Substances 0.000 claims abstract description 65
- 108700010013 HMGB1 Proteins 0.000 claims abstract description 47
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 34
- JUFFVKRROAPVBI-PVOYSMBESA-N chembl1210015 Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(=O)N[C@H]1[C@@H]([C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO[C@]3(O[C@@H](C[C@H](O)[C@H](O)CO)[C@H](NC(C)=O)[C@@H](O)C3)C(O)=O)O2)O)[C@@H](CO)O1)NC(C)=O)C(=O)NCC(=O)NCC(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CO)C(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 JUFFVKRROAPVBI-PVOYSMBESA-N 0.000 claims abstract description 31
- 108010011459 Exenatide Proteins 0.000 claims abstract description 30
- 229960001519 exenatide Drugs 0.000 claims abstract description 28
- 150000001413 amino acids Chemical group 0.000 claims abstract description 27
- 102000004196 processed proteins & peptides Human genes 0.000 claims abstract description 27
- 229920001184 polypeptide Polymers 0.000 claims abstract description 26
- 238000002360 preparation method Methods 0.000 claims abstract description 15
- 102000003779 Dipeptidyl-peptidases and tripeptidyl-peptidases Human genes 0.000 claims abstract description 13
- 108090000194 Dipeptidyl-peptidases and tripeptidyl-peptidases Proteins 0.000 claims abstract description 13
- 230000003110 anti-inflammatory effect Effects 0.000 claims abstract description 12
- 238000005516 engineering process Methods 0.000 claims abstract description 6
- 239000002773 nucleotide Substances 0.000 claims abstract description 5
- 125000003729 nucleotide group Chemical group 0.000 claims abstract description 5
- 239000013604 expression vector Substances 0.000 claims abstract description 3
- 102000055207 HMGB1 Human genes 0.000 claims abstract 3
- 101100339431 Arabidopsis thaliana HMGB2 gene Proteins 0.000 claims description 46
- 101150021904 HMGB1 gene Proteins 0.000 claims description 46
- 238000000034 method Methods 0.000 claims description 31
- 239000003814 drug Substances 0.000 claims description 18
- 108091008146 restriction endonucleases Proteins 0.000 claims description 13
- 201000001421 hyperglycemia Diseases 0.000 claims description 7
- 238000005304 joining Methods 0.000 claims description 2
- 238000010647 peptide synthesis reaction Methods 0.000 claims description 2
- 239000008280 blood Substances 0.000 abstract description 18
- 210000004369 blood Anatomy 0.000 abstract description 18
- 108090000623 proteins and genes Proteins 0.000 abstract description 13
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 abstract description 7
- 239000008103 glucose Substances 0.000 abstract description 7
- 238000003786 synthesis reaction Methods 0.000 abstract description 6
- 102000004169 proteins and genes Human genes 0.000 abstract description 5
- 238000003776 cleavage reaction Methods 0.000 abstract description 2
- 238000010276 construction Methods 0.000 abstract description 2
- 230000003247 decreasing effect Effects 0.000 abstract description 2
- 238000000746 purification Methods 0.000 abstract description 2
- 230000007017 scission Effects 0.000 abstract description 2
- 230000015572 biosynthetic process Effects 0.000 abstract 2
- 239000003472 antidiabetic agent Substances 0.000 abstract 1
- 230000028709 inflammatory response Effects 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 102100037907 High mobility group protein B1 Human genes 0.000 description 47
- 210000004027 cell Anatomy 0.000 description 28
- 235000001014 amino acid Nutrition 0.000 description 19
- 229940024606 amino acid Drugs 0.000 description 19
- 230000006870 function Effects 0.000 description 18
- 125000003275 alpha amino acid group Chemical group 0.000 description 14
- 102000004889 Interleukin-6 Human genes 0.000 description 13
- 108090001005 Interleukin-6 Proteins 0.000 description 13
- 229940100601 interleukin-6 Drugs 0.000 description 13
- 206010012601 diabetes mellitus Diseases 0.000 description 11
- 239000000413 hydrolysate Substances 0.000 description 11
- 229940079593 drug Drugs 0.000 description 10
- 230000007062 hydrolysis Effects 0.000 description 10
- 238000006460 hydrolysis reaction Methods 0.000 description 10
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 10
- 102000004877 Insulin Human genes 0.000 description 9
- 108090001061 Insulin Proteins 0.000 description 9
- 238000002474 experimental method Methods 0.000 description 9
- 206010061218 Inflammation Diseases 0.000 description 8
- 238000013461 design Methods 0.000 description 8
- 230000004054 inflammatory process Effects 0.000 description 8
- 238000012360 testing method Methods 0.000 description 8
- 238000010353 genetic engineering Methods 0.000 description 7
- 238000001727 in vivo Methods 0.000 description 7
- 230000003914 insulin secretion Effects 0.000 description 7
- 210000004153 islets of langerhan Anatomy 0.000 description 7
- 108020004999 messenger RNA Proteins 0.000 description 7
- 201000010099 disease Diseases 0.000 description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 6
- 230000002218 hypoglycaemic effect Effects 0.000 description 6
- 108020003175 receptors Proteins 0.000 description 6
- 102000005962 receptors Human genes 0.000 description 6
- 238000011160 research Methods 0.000 description 6
- 210000001519 tissue Anatomy 0.000 description 6
- 102000004190 Enzymes Human genes 0.000 description 5
- 108090000790 Enzymes Proteins 0.000 description 5
- 230000023555 blood coagulation Effects 0.000 description 5
- 229940088598 enzyme Drugs 0.000 description 5
- 230000002757 inflammatory effect Effects 0.000 description 5
- 229940125396 insulin Drugs 0.000 description 5
- 238000004519 manufacturing process Methods 0.000 description 5
- HTQBXNHDCUEHJF-XWLPCZSASA-N Exenatide Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)NCC(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CO)C(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 HTQBXNHDCUEHJF-XWLPCZSASA-N 0.000 description 4
- 101710198884 GATA-type zinc finger protein 1 Proteins 0.000 description 4
- 102400000322 Glucagon-like peptide 1 Human genes 0.000 description 4
- DTHNMHAUYICORS-KTKZVXAJSA-N Glucagon-like peptide 1 Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1N=CNC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 DTHNMHAUYICORS-KTKZVXAJSA-N 0.000 description 4
- 108091028043 Nucleic acid sequence Proteins 0.000 description 4
- 238000005336 cracking Methods 0.000 description 4
- 238000011161 development Methods 0.000 description 4
- 230000018109 developmental process Effects 0.000 description 4
- 230000004927 fusion Effects 0.000 description 4
- 238000009413 insulation Methods 0.000 description 4
- 230000010534 mechanism of action Effects 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- 241000894007 species Species 0.000 description 4
- 108020004414 DNA Proteins 0.000 description 3
- -1 IL- Proteins 0.000 description 3
- 108010002352 Interleukin-1 Proteins 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- 229940100389 Sulfonylurea Drugs 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 210000000227 basophil cell of anterior lobe of hypophysis Anatomy 0.000 description 3
- 210000004204 blood vessel Anatomy 0.000 description 3
- 230000006957 competitive inhibition Effects 0.000 description 3
- 230000006378 damage Effects 0.000 description 3
- 108020001507 fusion proteins Proteins 0.000 description 3
- 102000037865 fusion proteins Human genes 0.000 description 3
- 230000007246 mechanism Effects 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- 238000002054 transplantation Methods 0.000 description 3
- 108010005094 Advanced Glycation End Products Proteins 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 2
- 102000004127 Cytokines Human genes 0.000 description 2
- 108090000695 Cytokines Proteins 0.000 description 2
- 108010016626 Dipeptides Proteins 0.000 description 2
- 241000270431 Heloderma suspectum Species 0.000 description 2
- 208000032843 Hemorrhage Diseases 0.000 description 2
- 101710185235 High mobility group protein 1 Proteins 0.000 description 2
- 101710168537 High mobility group protein B1 Proteins 0.000 description 2
- 101001025337 Homo sapiens High mobility group protein B1 Proteins 0.000 description 2
- 108090001007 Interleukin-8 Proteins 0.000 description 2
- 101710151805 Mitochondrial intermediate peptidase 1 Proteins 0.000 description 2
- 102000035195 Peptidases Human genes 0.000 description 2
- 108091005804 Peptidases Proteins 0.000 description 2
- 101001032756 Rattus norvegicus Granzyme-like protein 1 Proteins 0.000 description 2
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 2
- 125000000539 amino acid group Chemical group 0.000 description 2
- 230000003042 antagnostic effect Effects 0.000 description 2
- 230000008485 antagonism Effects 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 208000037976 chronic inflammation Diseases 0.000 description 2
- 208000037893 chronic inflammatory disorder Diseases 0.000 description 2
- 238000005520 cutting process Methods 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- XZWYZXLIPXDOLR-UHFFFAOYSA-N metformin Chemical compound CN(C)C(=N)NC(N)=N XZWYZXLIPXDOLR-UHFFFAOYSA-N 0.000 description 2
- 210000000496 pancreas Anatomy 0.000 description 2
- 230000036285 pathological change Effects 0.000 description 2
- 231100000915 pathological change Toxicity 0.000 description 2
- 208000037920 primary disease Diseases 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 235000019833 protease Nutrition 0.000 description 2
- 235000018102 proteins Nutrition 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 238000003757 reverse transcription PCR Methods 0.000 description 2
- 230000002441 reversible effect Effects 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 210000002700 urine Anatomy 0.000 description 2
- 210000003462 vein Anatomy 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
- 206010007191 Capillary fragility Diseases 0.000 description 1
- 102000014914 Carrier Proteins Human genes 0.000 description 1
- 108010078791 Carrier Proteins Proteins 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 108010062466 Enzyme Precursors Proteins 0.000 description 1
- 102000010911 Enzyme Precursors Human genes 0.000 description 1
- 108700024394 Exon Proteins 0.000 description 1
- 108010014173 Factor X Proteins 0.000 description 1
- 101100339424 Homo sapiens HMGB1 gene Proteins 0.000 description 1
- 101000831567 Homo sapiens Toll-like receptor 2 Proteins 0.000 description 1
- 101000669447 Homo sapiens Toll-like receptor 4 Proteins 0.000 description 1
- 102000004157 Hydrolases Human genes 0.000 description 1
- 108090000604 Hydrolases Proteins 0.000 description 1
- 208000013016 Hypoglycemia Diseases 0.000 description 1
- 108091092195 Intron Proteins 0.000 description 1
- 102000036770 Islet Amyloid Polypeptide Human genes 0.000 description 1
- 108010041872 Islet Amyloid Polypeptide Proteins 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical group OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- 206010027336 Menstruation delayed Diseases 0.000 description 1
- 125000001429 N-terminal alpha-amino-acid group Chemical group 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 108010009736 Protein Hydrolysates Proteins 0.000 description 1
- ZSJLQEPLLKMAKR-UHFFFAOYSA-N Streptozotocin Natural products O=NN(C)C(=O)NC1C(O)OC(CO)C(O)C1O ZSJLQEPLLKMAKR-UHFFFAOYSA-N 0.000 description 1
- 229940123464 Thiazolidinedione Drugs 0.000 description 1
- 102100024333 Toll-like receptor 2 Human genes 0.000 description 1
- 102100039360 Toll-like receptor 4 Human genes 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 238000005267 amalgamation Methods 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 238000000137 annealing Methods 0.000 description 1
- 230000000798 anti-retroviral effect Effects 0.000 description 1
- 229940124522 antiretrovirals Drugs 0.000 description 1
- 230000001640 apoptogenic effect Effects 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- 150000001510 aspartic acids Chemical class 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 229940084891 byetta Drugs 0.000 description 1
- 210000004899 c-terminal region Anatomy 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000003638 chemical reducing agent Substances 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 229940121657 clinical drug Drugs 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 238000012407 engineering method Methods 0.000 description 1
- 229940047296 exenatide injection Drugs 0.000 description 1
- 239000013613 expression plasmid Substances 0.000 description 1
- 238000005227 gel permeation chromatography Methods 0.000 description 1
- 230000002641 glycemic effect Effects 0.000 description 1
- 210000002216 heart Anatomy 0.000 description 1
- 231100000652 hormesis Toxicity 0.000 description 1
- 102000053637 human HMGB1 Human genes 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 239000013002 intravenous (IV) drug Substances 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 239000007791 liquid phase Substances 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 210000003563 lymphoid tissue Anatomy 0.000 description 1
- 230000035800 maturation Effects 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 230000000291 postprandial effect Effects 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 238000011552 rat model Methods 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 239000002002 slurry Substances 0.000 description 1
- 239000007790 solid phase Substances 0.000 description 1
- 238000010532 solid phase synthesis reaction Methods 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- ZSJLQEPLLKMAKR-GKHCUFPYSA-N streptozocin Chemical compound O=NN(C)C(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O ZSJLQEPLLKMAKR-GKHCUFPYSA-N 0.000 description 1
- 229960001052 streptozocin Drugs 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 238000002626 targeted therapy Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 150000001467 thiazolidinediones Chemical class 0.000 description 1
- 208000037816 tissue injury Diseases 0.000 description 1
- 230000017423 tissue regeneration Effects 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 230000002103 transcriptional effect Effects 0.000 description 1
- 238000010361 transduction Methods 0.000 description 1
- 230000026683 transduction Effects 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
Images
Landscapes
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Abstract
Description
Claims (10)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2011103427518A CN102443064A (zh) | 2011-11-03 | 2011-11-03 | 一种基于凝血酶活性的双靶向作用的嵌合多肽及其应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2011103427518A CN102443064A (zh) | 2011-11-03 | 2011-11-03 | 一种基于凝血酶活性的双靶向作用的嵌合多肽及其应用 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN102443064A true CN102443064A (zh) | 2012-05-09 |
Family
ID=46006033
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN2011103427518A Pending CN102443064A (zh) | 2011-11-03 | 2011-11-03 | 一种基于凝血酶活性的双靶向作用的嵌合多肽及其应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN102443064A (zh) |
Cited By (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2913058A1 (en) * | 2012-10-25 | 2015-09-02 | Genomix Co., Ltd. | Novel method for treating cardiac infarction using hmgb1 fragment |
US9688733B2 (en) | 2012-10-25 | 2017-06-27 | Genomix Co., Ltd. | Method for treating spinal cord injury using HMGB1 fragment |
US9919010B2 (en) | 2008-04-30 | 2018-03-20 | Genomix Co., Ltd. | Method for collecting functional cells in vivo with high efficiency |
US10364276B2 (en) | 2011-04-26 | 2019-07-30 | StemRIM Inc. | Peptide for inducing regeneration of tissue and use thereof |
US11191786B2 (en) | 2009-10-28 | 2021-12-07 | StemRIM Inc. | Agents for promoting tissue regeneration by recruiting bone marrow mesenchymal stem cells and/or pluripotent stem cells into blood |
US11298403B2 (en) | 2017-12-01 | 2022-04-12 | StemRIM Inc. | Therapeutic agent for inflammatory bowel disease |
US11969459B2 (en) | 2017-01-27 | 2024-04-30 | StemRIM Inc. | Therapeutic agent for cardiomyopathy, old myocardial infarction and chronic heart failure |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101528266A (zh) * | 2006-09-15 | 2009-09-09 | 克雷毕里斯治疗股份公司 | Hmgb1的a盒和hmgb1的a盒变体的聚合体缀合物 |
CN101698681A (zh) * | 2008-10-10 | 2010-04-28 | 暨南大学 | 一种双靶向作用的嵌合多肽及其应用 |
-
2011
- 2011-11-03 CN CN2011103427518A patent/CN102443064A/zh active Pending
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101528266A (zh) * | 2006-09-15 | 2009-09-09 | 克雷毕里斯治疗股份公司 | Hmgb1的a盒和hmgb1的a盒变体的聚合体缀合物 |
CN101698681A (zh) * | 2008-10-10 | 2010-04-28 | 暨南大学 | 一种双靶向作用的嵌合多肽及其应用 |
Non-Patent Citations (1)
Title |
---|
张艳等: "人HMGB1A box和B box cDNA的克隆与表达", 《世界华人消化杂志》, vol. 12, no. 6, 30 June 2004 (2004-06-30), pages 1365 - 1368 * |
Cited By (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9919010B2 (en) | 2008-04-30 | 2018-03-20 | Genomix Co., Ltd. | Method for collecting functional cells in vivo with high efficiency |
US11197895B2 (en) | 2008-04-30 | 2021-12-14 | StemRIM Inc. | Method for collecting functional cells in vivo with high efficiency |
US11191786B2 (en) | 2009-10-28 | 2021-12-07 | StemRIM Inc. | Agents for promoting tissue regeneration by recruiting bone marrow mesenchymal stem cells and/or pluripotent stem cells into blood |
US10364276B2 (en) | 2011-04-26 | 2019-07-30 | StemRIM Inc. | Peptide for inducing regeneration of tissue and use thereof |
US10550165B2 (en) | 2011-04-26 | 2020-02-04 | StemRIM Inc. | Peptide for inducing regeneration of tissue and use thereof |
EP2913058A1 (en) * | 2012-10-25 | 2015-09-02 | Genomix Co., Ltd. | Novel method for treating cardiac infarction using hmgb1 fragment |
CN104884076A (zh) * | 2012-10-25 | 2015-09-02 | 吉诺米克斯股份有限公司 | 利用了hmgb1片段的新型心肌梗塞的治疗方法 |
EP2913058A4 (en) * | 2012-10-25 | 2016-04-13 | Genomix Co Ltd | NOVEL METHOD FOR TREATING HEART INFARCTION WITH AN HMGB1 FRAGMENT |
US9623078B2 (en) | 2012-10-25 | 2017-04-18 | Genomix Co., Ltd. | Method for treating cardiac infarction using HMGB1 fragment |
US9688733B2 (en) | 2012-10-25 | 2017-06-27 | Genomix Co., Ltd. | Method for treating spinal cord injury using HMGB1 fragment |
US11969459B2 (en) | 2017-01-27 | 2024-04-30 | StemRIM Inc. | Therapeutic agent for cardiomyopathy, old myocardial infarction and chronic heart failure |
US11298403B2 (en) | 2017-12-01 | 2022-04-12 | StemRIM Inc. | Therapeutic agent for inflammatory bowel disease |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN102443064A (zh) | 一种基于凝血酶活性的双靶向作用的嵌合多肽及其应用 | |
CN102292347A (zh) | 胰高血糖素类似物 | |
CN106220724B (zh) | 人成纤维细胞生长因子21重组蛋白及其制备方法和应用 | |
CN102153652A (zh) | 一种融合蛋白的表达方法及用途 | |
CN106432509B (zh) | 一种治疗代谢疾病的重组人成纤维细胞生长因子21融合蛋白及其制备方法和应用 | |
CN113265007B (zh) | 一种治疗代谢疾病的融合蛋白及其制备方法和应用 | |
CN101240033B (zh) | 一种促胰岛素分泌肽与人血清白蛋白的融合蛋白及其制备方法 | |
CN102295695B (zh) | 重组人促卵泡激素及其制备 | |
CN101003574B (zh) | 长效降血糖肽的重组表达及其在糖尿病治疗药物中的应用 | |
CN112851791B (zh) | 一种新型抗代谢紊乱的fgf类似物及其应用 | |
CN106397606B (zh) | 一种多肽复合物作为sst药物载体的应用、方法及其融合蛋白复合物 | |
CN113105561B (zh) | 一种双靶点融合蛋白的制备方法和应用 | |
CN101935346A (zh) | 突变的人源成纤维生长因子及在治疗内分泌疾病中的用途 | |
CN101698681B (zh) | 一种双靶向作用的嵌合多肽及其应用 | |
CN111808186B (zh) | 一种人源性分泌型fndc5蛋白及其制备方法和用途 | |
CN101824388A (zh) | 一种糖尿病食疗酵母及其构建方法 | |
KR20130021315A (ko) | Dkk2 단백질 또는 그 유전자를 포함하는 발기부전 예방 또는 치료용 조성물 및 그의 용도 | |
CN114621327A (zh) | GLP-1、GIP和Gcg多重受体激动蛋白质 | |
CN100535005C (zh) | 长链人胰岛素样生长因子(lr3igf-1)及其制备和应用方法 | |
CN101062948B (zh) | 单体速效胰岛素及其制法和用途 | |
CN113476591B (zh) | 一种乳源多肽衍生物在制备糖尿病防治药物、保健品以及食品添加物中的应用 | |
CN106478803B (zh) | 花姬蛙促胰岛素释放肽及其基因和在制药中的应用 | |
CN105348380B (zh) | 犬成纤维细胞生长因子21及其在治疗犬内分泌疾病中的用途 | |
CN114617956A (zh) | 一种高效降糖的蛋白质药物 | |
CN117510646A (zh) | 一种双功能融合蛋白及其用途 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
ASS | Succession or assignment of patent right |
Owner name: GUANGZHOU DONGLAI BIOTECHNOLOGY CO., LTD. Free format text: FORMER OWNER: LIU YU Effective date: 20120910 |
|
C41 | Transfer of patent application or patent right or utility model | ||
TA01 | Transfer of patent application right |
Effective date of registration: 20120910 Address after: 510655, Guangdong province Guangzhou Yuexiu District martyrs South Road No. 23, building 201, building Applicant after: GUANGZHOU DONGLAI BIOTECHNOLOGY CO., LTD. Address before: Fuying yuan a cross road 510655 in Guangdong province Guangzhou City Village 7 Building 101 room Applicant before: Liu Yu |
|
C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20120509 |